Awareness of breast cancer heterogeneity strikingly increased in the last decade in parallel with the development of highthrouput molecular tests. Beyond the clear usefulness of antiestrogen treatment in luminal tumors and trastuzumab in HER2-positive tumors, breast cancer subtypes may have additional clinical and predictive roles that can be relevant to clinical practice. In this article, we discuss the significance of molecular subtypes in the systemic treatment of early staged breast tumors smaller than 1cm (T1a,bN0M0) and suggest new strategies for future treatment recommendations for these patients.
3

Background
Screening and increased awareness have led to a rise in the detection of T 1 breast tumors that are generally estimated to have a low risk of recurrence after loco-regional treatment (1) (2) (3) (4) .
However, even small tumors can have an aggressive behaviour. This population of patients suffer from low representation in clinical trials which leads to a situation where medical oncologists lack high level evidence data that can guide them in the treatment of these patients. Tumor size and nodal involvement remain among the most important clinicpathological prognostic factors in breast cancer, which puts T 1a,b N 0 (<1cm) tumors in a group of a generally low risk of recurrence population. Information on T 1a,b N 0 from large population databases of untreated patients demonstrates relatively low cancer mortality rates at 15 years (<10%), with much higher death rates from other causes in women older than 50y (5, 6) . However, it has been shown that about 25% of all relapses of small lobular/ductal cancers occur beyond 10 years (7). High grade, young age, high proliferation and vascular invasion are considered adverse prognostic signs even among T 1a,b N 0 tumors suggesting a potential benefit of more aggressive therapy in women diagnosed with tumors harboring any/all of these features (8) (9) (10) (11) . Furthermore, the classification of breast cancers into different sub-types (luminal A, Luminal B, triple negative, and HER2 positive), appears also to affect prognosis and treatment decisions in such early cases (10, 12, 13) . This classification was first based only on histology features (estrogen receptor [ER] , progesterone receptor and HER2) but later on it was shown that the differences are also reflected by the mRNA expression profiles (14, 15) . (18) . Hence, based on the current data, it appears that women with small size, node-negative breast cancer are at higher risk of relapse if they have a HER2-positive or TNBC, while for luminal A and B cancers the risk is less clear.
On the Horizon
Luminal tumors
In the past decade, several genomic signatures emerged as useful tools to define patients at high risk of recurrence who might benefit more of the addition of adjuvant chemotherapy (19) . The Oncotype DX® 21-gene recurrence score (RS) assay is able to predict risk for distant recurrence among ER positive breast cancers treated with tamoxifen (20 from being prognostic, in two retrospective studies involving both node-negative and nodepositive patients, Oncotype DX® was found to be predictive for the chemotherapy benefit (21, 22) . Therefore it was endorsed by the NCCN for ER positive tumors with a tumor size >0.5 cm (T1b) in order to decide whether to give chemotherapy. In the NSABP trials that evaluated the Oncotype DX®, the distribution of the recurrence scores did not differ according to the size of the tumors and 15-16% of the T 1a,b N 0 tumors were considered at high risk (20, 23) . In a population-based retrospective study, T 1a,b N 0 tumors with high RS (>31)
were associated with a 10.1% risk of breast cancer death at 10 years compared to 1.3% in the low risk group (24) .
The MammaPrint® 70-gene signature has been previously validated as an independent prognostic factor in node-negative and node-positive breast cancer (25) . Mook et al. evaluated the accuracy of the 70-gene signature in T1 breast cancer irrespective of nodal involvement, and it was found to be an independent prognostic factor for breast cancer survival at 10 years (26) . These data show that the 70-gene signature can also help to individualise the adjuvant treatment recommendations in this population. 
HER2-enriched tumors
Five major randomised studies have shown that trastuzmab improves disease-free survival (DFS) and overall survival (OS) in the adjuvant setting when added to backbone chemotherapy in HER2 positive breast cancer (28-31); however, none of them recruited patients with T 1a,b N 0 except the BCIRG006 trial that randomly assigned 3222 women with HER2-positive early-stage breast cancer to receive doxorubicin and cyclophosphamide followed by docetaxel every 3 weeks, the same regimen plus trastuzumab or docetaxel and carboplatin plus trastuzumab (29) . Despite this fact, most clinical guidelines and most clinicians, as demonstrated in practice surveys, recommend giving trastuzumab for these small tumors, particularly T 1b tumors (32) . This is influenced by the significantly higher risk of relapse in HER2-positive patients (13, 16) . Nevertheless, it is also true that medical oncologists might be over treating a large fraction of these patients by offering the classic chemotherapy (anthracycline-taxane) plus trastuzumab combination. The REMAGUS French against cancer is the quantification of tumor-infiltrating lymphocytics (TILs). TILs were found to be in greater numbers in the HER2 and TNBC compared to the luminal subtypes (35) . In the FinHER trial, which randomised patients with HER2 positive breast cancers to 9 weeks of trastuzumab or no trastuzumab in the adjuvant setting, each 10% increase in lymphocytic infiltration was significantly associated with decreased distant recurrence in patients randomized to trastuzumab arm (36) . This data supports the role of anti-tumor immunity in the efficacy of trastuzumab. In addition, patients with HER2 positive disease and high TILs were found to benefit more from adjuvant anthracycline-based chemotherapy as observed in the BIG02-98 randomized phase III trial (35) . This suggests that TILs may be used to define patients with T 1a,b N 0 that would derive the highest benefit of trastuzumab and chemotherapy in the adjuvant setting.
Triple negative
TNBCs, which account for 15-20% of all invasive breast cancers, have an aggressive nature and increased risk of relapse and breast cancer related deaths compared with other subtypes (37) . Although from a clinical point of view, TNBCs are managed as one group, recent studies have shown that TNBCs are composed of an heterogeneous group of diseases with different biologies and clinical behaviors (38) (39) (40) . Current guidelines suggest adjuvant chemotherapy for patients with tumor size > 0.5cm (T1b) (41) . As no targeted therapy is currently available for the treatment of TNBCs, chemotherapy remains the only option.
Using gene expression profiling, seven distinct TNBC subtypes were identified and later on, a bioinformatics tool (TNBCtype) was developed to determine the TNBC molecular subtype (43) . The METABRIC consortium has also identified a large subgroup in the TNBC-basal-like tumors characterized by high-genomic instability (5 loss/8q gain/10p gain/12p gain) and relatively good long-term outcomes (27) . These molecular findings may guide future differential use of chemotherapy in T 1a,b N 0 cancers.
As described for HER2 positive patients, TILs were also found to be high in the TNBC breast cancer group (35) . Increasing 10% increments of infiltration were in fact associated with better prognosis, supporting a possible prognostic role of TILs in patients with small tumors.
The T 1a -T 1b cut-off
The classical staging system discriminates between T1a and T1b tumors (below or above 0.5 cm) based on large longitudinal cohorts that demonstrated minimal differences in prognosis between these groups with relative no impact on rate of breast cancer deaths (24) . As it is becoming clearer that the aggressiveness of the tumors is biology-driven rather than just influenced by tumor size, it is not obvious to artificially dichotomize patients using the 0.5 cm cut-off for diagnostic tests and treatment decisions. Moreover, there is evidence that tissue fixation and handling may affect tumor size (44, 45) . This includes the impact of preoperative biopsies, the effect of paraffin temperature, the pathological observer discrepancies and tendency for rounding results that have been shown to influence the correct estimation of tumor size (46) . In two recent reports there were no clear differences in outcomes between patients with T 1a and T 1b in HER2 positive tumors (18, 47) . Therefore oncologists should be cautious when making decision solely based on the distinction of whether the tumor is T 1a or T 1b . It is possible that in the near future assays such as Oncotype DX® or MammaPrint® and newer prognostic tools such TNBCtype will be of great help in defining the best treatment strategy for small tumors.
Concluding Remarks
The frequency of T 1a,b N 0 tumors is increasing sharply, especially in the western world as a result of mammography screening. The need to balance risks and benefits when deciding the treatment strategy in this relatively good prognostic group of patients is not trivial. The recent molecular classification of breast cancers, together with the development of new prognostic tools and omics-based clinical trials, may tailor more adequately the treatment recommendations for this population of breast cancers ( Table 1) . Instead of differentially dichotomising treatment decisions based on tumor size (>0.5cm), it is desirable that in the near future more individualized treatment strategies are applied which will take into account the biological aggressiveness of the tumor, the patient's clinical parameters (age, comorbidities) and preferences. 
